seofulvin • oxcarbazepine • phenytoin • rifampin • st. john’s wort • topiramate hiv protease inhibitors and non-nucleoside reverse transcriptase inhibitors : significant changes (increase or decrease) in the plasma levels of progestin have been noted in some cases of co-administration of hiv protease inhibitors. significant changes (increase or decrease) in the plasma levels of the progestin have been noted in some cases of co-administration with non-nucleoside reverse transcriptase inhibitors. antibiotics : there have been reports of pregnancy while taking hormonal contraceptives and antibiotics, but clinical pharmacokinetic studies have not shown consistent effects of antibiotics on plasma concentrations of synthetic steroids. consult the labeling of all concurrently-used drugs to obtain further information about interactions with hormonal contraceptives or the potential for enzyme alterations. 7.2 laboratory test interactions the pathologist should be advised of progestin therapy when relevant specimens are submitted. the following laboratory tests may be affected by progestins including medroxyprogesterone acetate: (a) plasma and urinary steroid levels are decreased (e.g., progesterone, estradiol, pregnanediol, testosterone, cortisol). (b) gonadotropin levels are decreased. (c) sex-hormone-binding-globulin concentrations are decreased. (d) protein-bound iodine and butanol extractable protein-bound iodine may increase. t3-uptake values may decrease. (e) coagulation test values for prothrombin (factor ii), and factors vii, viii, ix, and x may increase. (f) sulfobromophthalein and other liver function test values may be increased. (g) the effects of medroxyprogesterone acetate on lipid metabolism are inconsistent. both increases and decreases in total cholesterol, triglycerides, low-density lipoprotein (ldl) cholesterol, and high-density lipoprotein (hdl) cholesterol have been observed in studies.

nown if use of medroxyprogesterone acetate by younger women will reduce peak bone mass and increase the risk for osteoporotic fracture in later life. a study to assess the reversibility of loss of bmd in adolescents was conducted with medroxyprogesterone acetate. after discontinuing medroxyprogesterone acetate in these adolescents, mean bmd loss at the total hip and femoral neck did not fully recover by 5 years (60 months) post-treatment in the sub-group of adolescents who were treated for more than 2 years [see clinical studies (14.3) ]. similarly, in adults, there was only partial recovery of mean bmd at the total hip, femoral neck, and lumbar spine towards baseline by 2 years post-treatment [see clinical studies (14.2) ]. the use of medroxyprogesterone acetate is not recommended as a long-term (i.e., longer than 2 years) birth control method unless other options are considered inadequate. bmd should be evaluated when a woman needs to continue to use medroxyprogesterone acetate long-term. in adolescents, interpretation of bmd results should take into account patient age and skeletal maturity. other birth control methods should be considered in the risk/benefit analysis for the use of medroxyprogesterone acetate in women with osteoporosis risk factors. medroxyprogesterone acetate can pose an additional risk in patients with risk factors for osteoporosis (e.g., metabolic bone disease, chronic alcohol and/or tobacco use, anorexia nervosa, strong family history of osteoporosis or chronic use of drugs that can reduce bone mass such as anticonvulsants or corticosteroids). 5.2 thromboembolic disorders there have been reports of serious thrombotic events in women using medroxyprogesterone acetate (150 mg). however, medroxyprogesterone acetate has not been causally associated with the induction of thrombotic or thromboembolic disorders. any patient who develops thrombosis while undergoing therapy with medroxyprogesterone acetate should discontinue treatment unless she has no other acceptable options for birth control. do not re-administer medroxyprogesterone acetate pending examination if there is a sudden partial or complete loss of vision or if there is a sudden onset of proptosis, diplopia, or migraine. do not re-administer if examination reveals papilledema or retinal vascular lesions. 5.3 cancer risks breast cancer women who have or have had a history of breast cancer should not use hormonal contraceptives, including medroxyprogesterone acetate, because breast cancer may be hormonally sensitive [see contraindications (4) ]. women with a strong family history of breast cancer should be monitored with particular care. the results of five large case-control studies 1 assessing the association between depo-medroxyprogesterone acetate (dmpa) use and the risk of breast cancer are summarized in figure 1. three of the studies suggest a slightly increased risk of breast cancer in the overall population of users; these increased risks were statistically significant in one study. one recent us study 1 evaluated the recency and duration of use and found a statistically significantly increased risk of breast cancer in recent users (defined as last use within the past five years) who used dmpa for 12 months or longer; this is consistent with results of a previous study. figure 1 risk estimates for breast cancer in dmpa users odds ratio estimates were adjusted for the following covariates: lee et al. (1987): age, parity, and socioeconomic status. paul et al. (1989): age, parity, ethnic group, and year of interview. who (1991): age, center, and age at first live birth. shapiro et al. (2000): age, ethnic group, socioeconomic status, and any combined estrogen/progestogen oral contraceptive use. li et al. (2012): age, year, bmi, duration of oc use, number of full-term pregnancies, family history of breast cancer, and history of screening mammography. based on the published seer-18 2011 incidence rate (age-adjusted to the 2000 us standard population) of breast cancer for us women, all races, age 20 to 49 years, a doubling of risk would increase the incidence of breast cancer in women who use medroxyprogesterone acetate from about 72 to about 144 cases per 100,000 women. cervical cancer a statistically nonsignificant increase in rr estimates of invasive squamous-cell cervical cancer has been associated with the use of medroxyprogesterone acetate in women who were first exposed before the age of 35 years (rr 1.22 to 1.28 and 95% ci 0.93 to 1.70). the overall, nonsignificant relative rate of invasive squamous-cell cervical cancer in women who ever used medroxyprogesterone acetate was estimated to be 1.11 (95% ci 0.96 to 1.29). no trends in risk with duration of use or times since initial or most recent exposure were observed. other cancers long-term case-controlled surveillance of users of medroxyprogesterone acetate found no overall increased risk of ovarian or liver cancer. logarithmic scale.jpg 5.4 ectopic pregnancy be alert to the possibility of an ectopic pregnancy among women using medroxyprogesterone acetate who become pregnant or complain of severe abdominal pain. 5.5 anaphylaxis and anaphylactoid reaction anaphylaxis and anaphylactoid reaction have been reported with the use of medroxyprogesterone acetate. institute emergency medical treatment if an anaphylactic reaction occurs. 5.6 injection site reactions injection site reactions have been reported with use of medroxyprogesterone acetate [see adverse reactions (6.2) ] . persistent injection site reactions may occur after administration of medroxyprogesterone acetate due to inadvertent subcutaneous administration or release of the drug into the subcutaneous space while removing the needle [see dosage and administration (2.1) ] . 5.7 liver function discontinue medroxyprogesterone acetate use if jaundice or acute or chronic disturbances of liver function develop. do not resume use until markers of liver function return to normal and medroxyprogesterone acetate causation has been excluded. 5.8 convulsions there have been a few reported cases of convulsions in patients who were treated with medroxyprogesterone acetate. association with drug use or pre-existing conditions is not clear. 5.9 depression monitor patients who have a history of depression and do not re-administer medroxyprogesterone acetate if depression recurs. 5.10 bleeding irregularities most women using medroxyprogesterone acetate experience disruption of menstrual bleeding patterns. altered menstrual bleeding patterns include amenorrhea, irregular or unpredictable bleeding or spotting, prolonged spotting or bleeding, and heavy bleeding. rule out the possibility of organic pathology if abnormal bleeding persists or is severe, and institute appropriate treatment. as women continue using medroxyprogesterone acetate, fewer experience irregular bleeding and more experience amenorrhea. in clinical studies of medroxyprogesterone acetate, by month 12 amenorrhea was reported by 55% of women, and by month 24, amenorrhea was reported by 68% of women using medroxyprogesterone acetate. 5.11 weight gain women tend to gain weight while on therapy with medroxyprogesterone acetate. from an initial average body weight of 136 lb, women who completed 1 year of therapy with medroxyprogesterone acetate gained an average of 5.4 lb. women who completed 2 years of therapy gained an average of 8.1 lb. women who completed 4 years gained an average of 13.8 lb. women who completed 6 years gained an average of 16.5 lb. two percent of women withdrew from a large-scale clinical trial because of excessive weight gain. 5.12 carbohydrate metabolism a decrease in glucose tolerance has been observed in some patients on medroxyprogesterone acetate treatment. monitor diabetic patients carefully while receiving medroxyprogesterone acetate. 5.13 lactation detectable amounts of drug have been identified in the milk of mothers receiving medroxyprogesterone acetate. in nursing mothers treated with medroxyprogesterone acetate, milk composition, quality, and amount are not adversely affected. neonates and infants exposed to medroxyprogesterone from breast milk have been studied for developmental and behavioral effects through puberty. no adverse effects have been noted. 5.14 fluid retention because progestational drugs including medroxyprogesterone acetate may cause some degree of fluid retention, monitor patients with conditions that might be influenced by this condition, such as epilepsy, migraine, asthma, and cardiac or renal dysfunction. 5.15 return of fertility return to ovulation and fertility is likely to be delayed after stopping medroxyprogesterone acetate. in a large us study of women who discontinued use of medroxyprogesterone acetate to become pregnant, data are available for 61% of them. of the 188 women who discontinued the study to become pregnant, 114 became pregnant. based on life-table analysis of these data, it is expected that 68% of women who do become pregnant may conceive within 12 months, 83% may conceive within 15 months, and 93% may conceive within 18 months from the last injection. the median time to conception for those who do conceive is 10 months following the last injection with a range of 4 to 31 months, and is unrelated to the duration of use. no data are available for 39% of the patients who discontinued medroxyprogesterone acetate to become pregnant and who were lost to follow-up or changed their mind. 5.16 sexually transmitted diseases patients should be counseled that medroxyprogesterone acetate does not protect against hiv infection (aids) and other sexually transmitted diseases. 5.17 pregnancy although medroxyprogesterone acetate should not be used during pregnancy, there appears to be little or no increased risk of birth defects in women who have inadvertently been exposed to medroxyprogesterone acetate injections in early pregnancy. neonates exposed to medroxyprogesterone acetate in-utero and followed to adolescence showed no evidence of any adverse effects on their health including their physical, intellectual, sexual or social development. 5.18 monitoring a woman who is taking hormonal contraceptive should have a yearly visit with her healthcare provider for a blood pressure check and for other indicated healthcare. 5.19 interference with laboratory tests the use of medroxyprogesterone acetate may change the results of some laboratory tests, such as coagulation factors, lipids, glucose tolerance, and binding proteins. [see drug interactions (7.2) .]

rol methods are considered inadequate) due to the impact of long-term medroxyprogesterone acetate injectable suspension treatment on bone mineral density (bmd) [see warnings and precautions (5.1) ] . dosage does not need to be adjusted for body weight [see clinical studies (14.1) ] . to ensure the patient is not pregnant at the time of the first injection, the first injection should be given only during the first 5 days of a normal menstrual period; only within the first 5-days postpartum if not breast-feeding; and if exclusively breast-feeding, only at the sixth postpartum week. if the time interval between injections is greater than 13 weeks, the physician should determine that the patient is not pregnant before administering the drug. the efficacy of medroxyprogesterone acetate injectable suspension depends on adherence to the dosage schedule of administration. 2.2 switching from other methods of contraception when switching from other contraceptive methods, medroxyprogesterone acetate injectable suspension should be given in a manner that ensures continuous contraceptive coverage based upon the mechanism of action of both methods, (e.g., patients switching from oral contraceptives should have their first injection of medroxyprogesterone acetate injectable suspension on the day after the last active tablet or at the latest, on the day following the final inactive tablet).

www.fda.gov/medwatch. 6.1 clinical trials experience because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. in the two clinical trials with medroxyprogesterone acetate, over 3,900 women, who were treated for up to 7 years, reported the following adverse reactions, which may or may not be related to the use of medroxyprogesterone acetate. the population studied ranges in age from 15 to 51 years, of which 46% were white, 50% non-white, and 4.9% unknown race. the patients received 150 mg medroxyprogesterone acetate every 3-months (90 days). the median study duration was 13 months with a range of 1 to 84 months. fifty eight percent of patients remained in the study after 13 months and 34% after 24 months. table 1 adverse reactions that were reported by more than 5% of subjects body system* adverse reactions [incidence (%)] body as a whole headache (16.5%) abdominal pain/discomfort (11.2%) metabolic/nutritional increased weight > 10lbs at 24 months (37.7%) nervous nervousness (10.8%) dizziness (5.6%) libido decreased (5.5%) urogenital menstrual irregularities: (bleeding (57.3% at 12 months, 32.1% at 24 months) amenorrhea (55% at 12 months, 68% at 24 months) *body system represented from costart medical dictionary. table 2 adverse reactions that were reported by between 1 and 5% of subjects body system* adverse reactions [incidence (%)] body as a whole asthenia/fatigue (4.2%) backache (2.2%) dysmenorrhea (1.7%) hot flashes (1.0%) digestive nausea (3.3%) bloating (2.3%) metabolic/nutritional edema (2.2%) musculoskeletal leg cramps (3.7%) arthralgia (1.0%) nervous depression (1.5%) insomnia (1.0%) skin and appendages acne (1.2%) no hair growth/alopecia (1.1%) rash (1.1%) urogenital leukorrhea (2.9%) breast pain (2.8%) vaginitis (1.2%) * body system represented from costart medical dictionary. adverse reactions leading to study discontinuation in ≥2% of subjects: bleeding (8.2%), amenorrhea (2.1%), weight gain (2.0%) 6.2 post-marketing experience the following adverse reactions have been identified during post approval use of medroxyprogesterone acetate. because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. there have been cases of osteoporosis including osteoporotic fractures reported post-marketing in patients taking medroxyprogesterone acetate. table 3 adverse reactions reported during post-marketing experience body system* adverse reactions body as a whole chest pain, allergic reactions including angioedema, fever, injection site abscess † , injection site infection † , injection site nodule/lump, injection site pain/tenderness, injection site persistent atrophy/indentation/dimpling, injection-site reaction, lipodystrophy acquired, chills, axillary swelling cardiovascular syncope, tachycardia, thrombophlebitis, deep vein thrombosis, pulmonary embolus, varicose veins digestive changes in appetite, gastrointestinal disturbances, jaundice, excessive thirst, rectal bleeding hematologic and lymphatic anemia, blood dyscrasia musculoskeletal osteoporosis neoplasms cervical cancer, breast cancer nervous paralysis, facial palsy, paresthesia, drowsiness respiratory dyspnea and asthma, hoarseness skin and appendages hirsutism, excessive sweating and body odor, dry skin, scleroderma urogenital lack of return to fertility, unexpected pregnancy, prevention of lactation, changes in breast size, breast lumps or nipple bleeding, galactorrhea, melasma, chloasma, increased libido, uterine hyperplasia, genitourinary infections, vaginal cysts, dyspareunia * body system represented from costart medical dictionary. † injection site abscess and injection site infections have been reported; therefore strict aseptic injection technique should be followed when administering medroxyprogesterone acetate in order to avoid injection site infections [see dosage and administration (2.1) ].

seofulvin • oxcarbazepine • phenytoin • rifampin • st. john’s wort • topiramate hiv protease inhibitors and non-nucleoside reverse transcriptase inhibitors : significant changes (increase or decrease) in the plasma levels of progestin have been noted in some cases of co-administration of hiv protease inhibitors. significant changes (increase or decrease) in the plasma levels of the progestin have been noted in some cases of co-administration with non-nucleoside reverse transcriptase inhibitors. antibiotics : there have been reports of pregnancy while taking hormonal contraceptives and antibiotics, but clinical pharmacokinetic studies have not shown consistent effects of antibiotics on plasma concentrations of synthetic steroids. consult the labeling of all concurrently-used drugs to obtain further information about interactions with hormonal contraceptives or the potential for enzyme alterations. 7.2 laboratory test interactions the pathologist should be advised of progestin therapy when relevant specimens are submitted. the following laboratory tests may be affected by progestins including medroxyprogesterone acetate: (a) plasma and urinary steroid levels are decreased (e.g., progesterone, estradiol, pregnanediol, testosterone, cortisol). (b) gonadotropin levels are decreased. (c) sex-hormone-binding-globulin concentrations are decreased. (d) protein-bound iodine and butanol extractable protein-bound iodine may increase. t3-uptake values may decrease. (e) coagulation test values for prothrombin (factor ii), and factors vii, viii, ix, and x may increase. (f) sulfobromophthalein and other liver function test values may be increased. (g) the effects of medroxyprogesterone acetate on lipid metabolism are inconsistent. both increases and decreases in total cholesterol, triglycerides, low-density lipoprotein (ldl) cholesterol, and high-density lipoprotein (hdl) cholesterol have been observed in studies.

medroxyprogesterone acetate by younger women will reduce peak bone mass and increase the risk of osteoporotic fractures in later life. other than concerns about loss of bmd, the safety and effectiveness are expected to be the same for postmenarchal adolescents and adult women. 8.5 geriatric use this product has not been studied in post-menopausal women and is not indicated in this population. 8.6 renal impairment the effect of renal impairment on medroxyprogesterone acetate pharmacokinetics has not been studied. 8.7 hepatic impairment the effect of hepatic impairment on medroxyprogesterone acetate pharmacokinetics has not been studied. medroxyprogesterone acetate should not be used by women with significant liver disease and should be discontinued if jaundice or disturbances of liver function occur. [ see contraindications (4) and warnings and precautions (5.7) .]

es ring a and/or side-chain reduction, loss of the acetyl group, hydroxylation in the 2-, 6-, and 21-positions or a combination of these positions, resulting in more than 10 metabolites. excretion the concentrations of medroxyprogesterone acetate decrease exponentially until they become undetectable (<100 pg/ml) between 120 to 200 days following injection. using an unextracted radioimmunoassay procedure for the assay of medroxyprogesterone acetate in serum, the apparent half-life for medroxyprogesterone acetate following im administration of medroxyprogesterone acetate is approximately 50 days. most medroxyprogesterone acetate metabolites are excreted in the urine as glucuronide conjugates with only minor amounts excreted as sulfates. specific populations the effect of hepatic and/or renal impairment on the pharmacokinetics of medroxyprogesterone acetate is unknown.

munoassay procedure for the assay of medroxyprogesterone acetate in serum, the apparent half-life for medroxyprogesterone acetate following im administration of medroxyprogesterone acetate is approximately 50 days. most medroxyprogesterone acetate metabolites are excreted in the urine as glucuronide conjugates with only minor amounts excreted as sulfates. specific populations the effect of hepatic and/or renal impairment on the pharmacokinetics of medroxyprogesterone acetate is unknown.

total hip and femoral neck were similar. after stopping use of medroxyprogesterone acetate, there was partial recovery of bmd toward baseline values during the 2-year post-therapy period. longer duration of treatment was associated with less complete recovery during this 2-year period following the last injection. table 4 shows the change in bmd in women after 5 years of treatment with medroxyprogesterone acetate and in women in a control group, as well as the extent of recovery of bmd for the subset of the women for whom 2-year post treatment data were available. table 4. mean percent change from baseline in bmd in adults by skeletal site and cohort (5 years of treatment and 2 years of follow-up) time in study spine total hip femoral neck medroxyprogesterone acetate * control** medroxyprogesterone acetate* control** medroxyprogesterone acetate* control** 5 years -5.38% n=33 0.43% n=105 -5.16% n=21 0.19% n=65 -6.12% n=34 -0.27% n=106 7 years -3.13% n=12 0.53% n=60 -1.34% n=7 0.94% n=39 -5.38% n=13 -0.11% n=63 *the treatment group consisted of women who received medroxyprogesterone acetate for 5 years and were then followed for 2 years post-use (total time in study of 7 years). **the control group consisted of women who did not use hormonal contraception and were followed for 7 years. 14.3 bone mineral density changes in adolescent females (12 to 18 years of age) treated with medroxyprogesterone acetate the impact of medroxyprogesterone acetate (150 mg) use for up to 240 weeks (4.6 years) was evaluated in an open-label non-randomized clinical study in 389 adolescent females (12 to 18 years of age). use of medroxyprogesterone acetate was associated with a significant decline from baseline in bmd. partway through the trial, drug administration was stopped (at 120 weeks). the mean number of injections per medroxyprogesterone acetate user was 9.3. table 5 summarizes the study findings. the decline in bmd at total hip and femoral neck was greater with longer duration of use. the mean decrease in bmd at 240 weeks was more pronounced at total hip (-6.4%) and femoral neck (-5.4%) compared to lumbar spine (-2.1%). adolescents in the untreated cohort had an increase in bmd during the period of growth following menarche. however, the two cohorts were not matched at baseline for age, gynecologic age, race, bmd and other factors that influence the rate of acquisition of bmd. table 5. mean percent change from baseline in bmd in adolescents receiving ≥4 injections per 60-week period, by skeletal site and cohort duration of treatment medroxyprogesterone acetate (150 mg im) unmatched, untreated cohort n mean % change n mean % change total hip bmd week 60 (1.2 years) week 120 (2.3 years) week 240 (4.6 years) 113 73 28 -2.75 -5.40 -6.40 166 109 84 1.22 2.19 1.71 femoral neck bmd week 60 week 120 week 240 113 73 28 -2.96 -5.30 -5.40 166 108 84 1.75 2.83 1.94 lumbar spine bmd week 60 week 120 week 240 114 73 27 -2.47 -2.74 -2.11 167 109 84 3.39 5.28 6.40 bmd recovery post-treatment in adolescents longer duration of treatment and smoking were associated with less recovery of bmd following the last injection of medroxyprogesterone acetate. table 6 shows the extent of recovery of bmd up to 60 months post-treatment for adolescents who received medroxyprogesterone acetate for two years or less compared to more than two years. post-treatment follow-up showed that, in women treated for more than two years, only lumbar spine bmd recovered to baseline levels after treatment was discontinued. adolescents treated with medroxyprogesterone acetate for more than two years did not recover to their baseline bmd level at femoral neck and total hip even up to 60 months post-treatment. adolescents in the untreated cohort gained bmd throughout the trial period (data not shown) [see warnings and precautions (5.1)] . table 6: bmd recovery (months post-treatment) in adolescents by years of medroxyprogesterone acetate use (2 years or less vs. more than 2 years) duration of treatment 2 years or less more than 2 years n mean % change from baseline n mean % change from baseline total hip bmd end of treatment 12 m post-treatment 24 m post-treatment 36 m post-treatment 48 m post-treatment 60 m post-treatment 49 33 18 12 10 3 -1.5% -1.4% 0.3% 2.1% 1.3% 0.2% 49 24 17 11 9 2 -6.2% -4.6% -3.6% -4.6% -2.5% -1.0% femoral neck bmd end of treatment 12 m post-treatment 24 m post-treatment 36 m post-treatment 48 m post-treatment 60 m post-treatment 49 33 18 12 10 3 -1.6% -1.4% 0.5% 1.2% 2.0% 1.0% 49 24 17 11 9 2 -5.8% -4.3% -3.8% -3.8% -1.7% -1.9% lumbar spine bmd end of treatment 12 m post-treatment 24 m post-treatment 36 m post-treatment 48 m post-treatment 60 m post-treatment 49 33 18 12 10 3 -0.9% 0.4% 2.6% 2.4% 6.5% 6.2% 49 23 17 11 9 2 -3.5% -1.1% 1.9% 0.6% 3.5% 5.7% 14.4 bone fracture incidence in women treated with medroxyprogesterone acetate a retrospective cohort study to assess the association between medroxyprogesterone acetate injection and the incidence of bone fractures was conducted in 312,395 female contraceptive users in the uk. the incidence rates of fracture were compared between medroxyprogesterone acetate users and contraceptive users who had no recorded use of medroxyprogesterone acetate. the incident rate ratio (irr) for any fracture during the follow-up period (mean=5.5 years) was 1.41 (95% ci 1.35, 1.47). it is not known if this is due to medroxyprogesterone acetate use or to other related lifestyle factors that have a bearing on fracture rate. in the study, when cumulative exposure to medroxyprogesterone acetate was calculated, the fracture rate in users who received fewer than 8 injections was higher than that in women who received 8 or more injections. however, it is not clear that cumulative exposure, which may include periods of intermittent use separated by periods of non-use, is a useful measure of risk, as compared to exposure measures based on continuous use. there were very few osteoporotic fractures (fracture sites known to be related to low bmd) in the study overall, and the incidence of osteoporotic fractures was not found to be higher in medroxyprogesterone acetate users compared to non-users. importantly, this study could not determine whether use of medroxyprogesterone acetate has an effect on fracture rate later in life.

l llc morgantown, wv 26505 u.s.a. manufactured by: mylan laboratories limited bangalore, india march 2021